Schrödinger, Inc. Overview
Pro stress-test →Schrödinger, Inc. is an international scientific software and biotechnology company that specializes in developing computational tools and software for drug discovery and materials science. The company's software is used by pharmaceutical companies, biotech, tech, chemicals, energy, aerospace firms, and academic researchers to simulate and model molecular behavior, accelerating the design and development of new drugs and materials while reducing time and cost to market.
Strategic Profile
Pro stress-test →The company operates in two segments: Software, which transforms molecular discovery for life sciences and materials science industries, and Drug Discovery, which focuses on building a portfolio of preclinical and clinical programs internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger's technology platform combines physics-based modeling and machine learning to accelerate innovation in pharmaceutical and materials design.
Competitive Landscape
Pro stress-test →Schrödinger's competitors include Alivexis, Citrine Informatics, Aqemia, Isomorphic Laboratories, Oxford Drug Design, and others. The computational drug discovery space increasingly includes AI-native platforms like Insilico Medicine and InSilicoTrials. Schrödinger maintains differentiation through its physics-based computational approach, established enterprise customer base, and FEP+ gold-standard binding free energy platform.
Industry Context
Schrödinger, Inc. operates in Computational drug discovery software.
Key facts
Founded: 1990 · Headquarters: New York, US · Employees: ~800 · Revenue: N/A · Market cap: $1.08B